

**CALIFORNIA INSTITUTE FOR  
REGENERATIVE MEDICINE**  
**(A Component Unit of the State of California)**

Independent Auditor's Reports, Management's  
Discussion and Analysis, Basic Financial  
Statements and Supplementary Information

For the Year Ended June 30, 2021



Certified  
Public  
Accountants

**CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE**  
(A Component Unit of the State of California)  
For The Year Ended June 30, 2021

*Table of Contents*

	<i>Page</i>
<b>Independent Auditor’s Report</b> .....	1
<b>Management’s Discussion and Analysis (Unaudited)</b> .....	4
<b>Basic Financial Statements:</b>	
Statement of Net Position and Governmental Fund Balance Sheet.....	9
Statement of Activities and Governmental Fund Statement of Revenues, Expenditures and Changes in Fund Balance.....	10
Stem Cell Fund Statement of Expenditures - Budget and Actual.....	11
Notes to the Basic Financial Statements.....	12
<b>Supplementary Information:</b>	
Dolby Grant - Schedule of Revenues, Expenditures and Available Resources.....	19
Stem Cell Fund Combining Balance Sheet.....	20
Stem Cell Fund Combining Statement of Revenues, Expenditures and Changes in Fund Balance.....	21
<b>Other Report:</b>	
Independent Auditor’s Report on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with <i>Governmental Auditing Standards</i> .....	22



## Independent Auditor's Report

To the Members of the  
Independent Citizens Oversight Committee of the  
California Institute for Regenerative Medicine  
Oakland, California

### Report on the Financial Statements

We have audited the accompanying financial statements of the governmental activities and the major fund of the California Institute for Regenerative Medicine (CIRM), a component unit of the State of California, as of and for the year ended June 30, 2021, and the related notes to the financial statements, which collectively comprise CIRM's basic financial statements as listed in the table of contents.

### *Management's Responsibility for the Financial Statements*

Management is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

### *Auditor's Responsibility*

Our responsibility is to express opinions on these financial statements based on our audit. We conducted our audit in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement whether due to fraud or error.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinions.

## ***Opinions***

In our opinion, the financial statements referred to above present fairly, in all material respects, the respective financial position of the governmental activities and the major fund of CIRM as of June 30, 2021, and the respective changes in the financial position and the required budgetary comparison for the Stem Cell Fund for the year then ended in accordance with accounting principles generally accepted in the United States of America.

## ***Other Matters***

### ***Required Supplementary Information***

Accounting principles generally accepted in the United States of America require that the management's discussion and analysis as listed in the table of contents be presented to supplement the basic financial statements. Such information, although not a part of the basic financial statements, is required by the Governmental Accounting Standards Board who considers it to be an essential part of financial reporting for placing the basic financial statements in an appropriate operational, economic, or historical context. We have applied certain limited procedures to the required supplementary information in accordance with auditing standards generally accepted in the United States of America, which consisted of inquiries of management about the methods of preparing the information and comparing the information for consistency with management's responses to our inquiries, the basic financial statements, and other knowledge we obtained during our audit of the basic financial statements. We do not express an opinion or provide any assurance on the information because the limited procedures do not provide us with sufficient evidence to express an opinion or provide any assurance.

### ***Other Information***

Our audit was conducted for the purpose of forming opinions on the financial statements that collectively comprise CIRM's basic financial statements. The Dolby Grant schedule of revenues, expenditures and available resources, Stem Cell Fund Combining Balance Sheet and Stem Cell Fund Combining Statement of Revenues, Expenditures and Changes in Fund Balance (Combining Statements) are presented for purposes of additional analysis and are not a required part of the basic financial statements.

The Dolby Grant Schedule and Stem Cell Fund Combining Statements are the responsibility of management and were derived from and relate directly to the underlying accounting and other records used to prepare the basic financial statements. Such information has been subjected to the auditing procedures applied in the audit of the basic financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the basic financial statements or to the basic financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the Schedules are fairly stated, in all material respects, in relation to the basic financial statements as a whole.

### **Other Reporting Required by *Government Auditing Standards***

In accordance with *Government Auditing Standards*, we have also issued our report dated October 29, 2021, on our consideration of CIRM's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements and other matters. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on the effectiveness of CIRM's internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering CIRM's internal control over financial reporting and compliance.

*Macias Gini & O'Connell LLP*

Sacramento, California

October 29, 2021

**CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE**  
(A Component Unit of the State of California)  
Management's Discussion and Analysis (Unaudited)  
For the Year Ended June 30, 2021

Management of the California Institute for Regenerative Medicine (CIRM) is pleased to provide this overview and analysis of the financial activities of CIRM for the year ended June 30, 2021. We encourage readers to consider the information presented here in conjunction with the financial statements that follow this discussion.

**Financial Highlights**

All financial assets of CIRM continue to be devoted to providing funds for medical research and facilities, and the operations of CIRM.

- The net position of CIRM as of June 30, 2021, was \$297,584,273 compared to the end of the prior fiscal year balance of \$107,514,261. The increase is primarily due to the passage of Proposition (Prop) 14. See discussion below in Government-Wide Financial Analysis regarding the investment of CIRM grants.
- CIRM's cash and investments balance as of June 30, 2021, was \$261,388,514 an increase of \$191,648,169 from the balance on June 30, 2020, primarily due to the issuance of general obligation bonds under Prop 14 in April 2021.
- For the year ended June 30, 2021, CIRM had total revenues of \$298,575,327, of which \$117,820,852 was related to Prop 71 and \$180,754,475 related to Prop 14, representing an increase of \$147,306,187 from the prior year. Total expenses for fiscal year (FY) 2021 were \$108,505,316, of which \$106,916,156 was related to Prop 71 and \$1,589,160 to Prop 14, representing a \$44,480,838 decrease from the prior year.

**Overview of the Financial Statements**

This discussion and analysis is intended to serve as an introduction to CIRM's basic financial statements, which comprise the following components, in addition to management's discussion and analysis: 1) Government-wide financial statements, 2) Fund financial statements, and 3) Notes to the basic financial statements. The government-wide and fund financial statements are presented in a combined format as listed in the table of contents. Items in the adjustment column of each respective financial statement are discussed in Note 3.

**Government-Wide Financial Statements**

The government-wide financial statements are designed to provide readers with a broad overview of CIRM's finances, in a manner similar to a private-sector business.

The *statement of net position* presents information on all of CIRM's assets and liabilities, with the difference between the two reported as net position. Over time, increases or decreases in net position may serve as a useful indicator of whether the financial position of CIRM is improving or deteriorating.

**CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE**  
(A Component Unit of the State of California)  
Management's Discussion and Analysis (Unaudited) (Continued)  
For the Year Ended June 30, 2021

**Government-Wide Financial Statements (Continued)**

The *statement of activities* presents information showing how CIRM's net position changed during the most recent fiscal year. All changes in net position are reported as soon as the underlying event giving rise to the change occurs, regardless of the timing of related cash flows. Thus, revenues and expenses are reported in this statement for some items that will only result in cash flows in future fiscal periods (e.g., earned but unused compensated leave).

**Fund Financial Statements**

A fund is a grouping of related accounts that is used to maintain control over resources that have been segregated for specific activities or objectives. CIRM uses fund accounting to ensure and demonstrate compliance with finance-related legal requirements. CIRM reports one governmental-type fund, the Stem Cell Fund (Fund).

Governmental fund financial statements focus on *near-term inflows and outflows of spendable resources*, as well as on *balances of spendable resources* available at the end of the fiscal year. Such information may be useful in evaluating CIRM's near-term financing requirements.

Because the focus of governmental funds is narrower than that of the government-wide financial statements, it is useful to compare the information presented for the governmental fund with similar information presented for governmental activities. Both the governmental fund balance sheet and the governmental fund statement of revenues, expenditures and changes in fund balance provide a column detailing the differences (adjustments) between the governmental fund and governmental activities. These adjustments are discussed in further detail in Note 3 to the basic financial statements.

**Notes to the Basic Financial Statements**

The notes provide additional information that is essential to a full understanding of the data provided in the government-wide and fund financial statements. The notes to the basic financial statements can be found on the pages as listed in the table of contents of this report.

**Government-Wide Financial Analysis**

The government-wide financial statements provide long-term and short-term information about CIRM's overall financial condition. This analysis addresses the financial statements of CIRM as a whole.

As noted earlier, the combined net position may serve over time as a useful indicator of CIRM's financial position. As of June 30, 2021, CIRM's net position was \$297,584,273, all of which was unrestricted. Net position increased by \$190,070,011 from prior year net position of \$107,514,262, primarily due to the general obligation bond revenue of \$180,635,000 issued under Prop 14, which was mostly unexpended prior to fiscal year end.

**CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE**  
(A Component Unit of the State of California)  
Management's Discussion and Analysis (Unaudited) (Continued)  
For the Year Ended June 30, 2021

**Government-Wide Financial Analysis (Continued)**

For the year ended June 30, 2021, total revenues are a combined increase from Proposition 14 Bond Proceeds (GO Bonds) in the amount of \$180,635,000 and a decrease attributed to a reduction in Proposition 71 Bond Proceeds (GO Bonds) and Commercial Paper (CP) receipts in the amount of \$114,060,000 (a decrease of \$9,940,000 from FY 2019/20). Investment earnings decreased \$9,082,783. In addition, Prop 71 expenses as of June 30, 2021, decreased by \$46,069,998 from June 30, 2020, due to a decrease in grant award expense of \$45,542,802 and a decrease in operations expense of \$527,196. The decrease in award expense is due to the reduced number of new grant awards, as well as the payment schedule in accordance with the milestone-based terms and conditions. Prop 14 expenses reflect \$1,500,000 in grant awards and \$89,160 related to operations expenses.

The recipients of CIRM's grants are required to use the granted funds to construct or acquire research facilities or to perform research. Expenditures of that type may be reported by the grant recipients as investments in capital assets of the grant recipients. CIRM will work with its grantees to ensure proper reporting of these capital expenditures. Grants made by CIRM are treated as expenses of CIRM rather than investments in capital assets of CIRM even though (i) the recipients of the grants may be required to use the granted funds in a manner that is treated as investments in capital assets of the grant recipients and (ii) as a condition of each grant, CIRM obtains certain rights to use, control or benefit from the discoveries or information developed by the grant recipients.

Condensed Government Wide Statement of Net Position  
(Amounts Expressed in Thousands)

	June 30	
	2021	2020
Current and other assets	\$302,400	\$111,649
Capital assets	-	8
Total Assets	302,490	111,657
Current and other liabilities	1,318	809
Long-term liabilities	3,498	3,334
Total liabilities	4,816	4,143
Net position		
Net investment in capital assets	-	8
Unrestricted	297,584	107,506
Total net position	\$297,584	\$107,514



**CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE**  
(A Component Unit of the State of California)  
Management's Discussion and Analysis (Unaudited) (Continued)  
For the Year Ended June 30, 2021

**Government-Wide Financial Analysis (Continued)**

Condensed Government Wide Statement of Activities  
(Amounts Expressed in Thousands)

	June 30	
	2021	2020
Revenues:		
GO bond revenue	\$284,695	\$64,000
CP revenue	10,000	60,000
Licensing and royalty revenue	3	-
Interest on loans	679	1,871
Proceeds from loan repayment	-	13,233
Investment earnings	3,198	12,165
Total revenues	298,575	151,269
Expenses:		
State operations	13,161	13,599
Research grants	95,344	139,387
Total expenses	108,505	152,986
Change in net position	190,070	1,717
Net position, beginning of year	107,514	109,231
Net position, end of year	\$297,584	\$107,514

For fund financial statements refer to pages 9 and 10. For fund budget to actual comparison refer to page 11.

**Financial Analysis of CIRM's Combined Stem Cell Funds**

The focus of the Stem Cell Fund is to provide information on near-term inflows, outflows, and balances of spendable resources. Such information is useful in assessing the Fund's financing requirements. In particular, fund balance may serve as a useful measure of the Fund's net resources available for spending for program purposes at the end of the fiscal year.

As of the year ended June 30, 2021, the Fund reported ending fund balance of \$260,449,363 compared to the June 30, 2020, ending fund balance of \$70,816,909. The combined Fund's major source of revenue is GO Bonds for both Prop 71 and Prop 14, in addition to Commercial Paper for Prop 71. The Fund's major expenditures are research grants and state operations.

**CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE**  
(A Component Unit of the State of California)  
Management's Discussion and Analysis (Unaudited) (Continued)  
For the Year Ended June 30, 2021

**Stem Cell Fund Budgetary Highlights**

The Stem Cell Fund budget projected a combined total expenditures of \$265,337,225. Actual expenditures were less than budgeted projections by \$157,073,009 in the categories of research grants, salaries and operating expenditures. Stem Cell Fund Actual includes expenditures for the current and prior year budgeted appropriations. During the FY 2020/21, the State Treasurer issued \$294,695,000 in Bond Proceeds and Commercial Paper funding.

**Contacting CIRM's Financial Management**

This financial report is designed to provide a general overview of CIRM's finances, and to demonstrate CIRM's accountability for the money it receives. If you have questions about this report, or need additional financial information, please contact the California Institute for Regenerative Medicine, 1999 Harrison Street, Suite 1650, Oakland, California 94612.

**CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE**  
**(A Component Unit of the State of California)**  
Statement of Net Position and Governmental Fund Balance Sheet  
June 30, 2021

	Stem Cell Fund	Adjustments (Note 3)	Statement of Net Position
<b>Assets</b>			
Cash and investments	\$ 261,388,514	\$ -	\$ 261,388,514
Accounts receivable	42,288	-	42,288
Due from other State funds	267,120	-	267,120
Loans receivable	22,999,933	-	22,999,933
Interest receivable	17,702,216	-	17,702,216
Total assets	302,400,071	-	302,400,071
<b>Liabilities</b>			
Accounts payable	923,987	-	923,987
Due to other State funds	324,572	-	324,572
Long term Liabilities			
Due within one year	-	69,000	69,000
Due in more than one year	-	3,498,239	3,498,239
Total liabilities	1,248,559	3,567,239	4,815,798
<b>Deferred inflows of resources</b>			
Unavailable loans and interest receivable	40,702,149	(40,702,149)	-
<b>Fund balance/net position:</b>			
Fund balance			
Committed	260,449,363	(260,449,363)	-
Total liabilities and deferred inflows and fund balance	\$ 302,400,071		
Net position			
Unrestricted		\$ 297,584,273	\$ 297,584,273

See accompanying notes to the financial statements.

**CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE**  
**(A Component Unit of the State of California)**

Statement of Activities and Governmental Fund Statement of Revenues, Expenditures and  
Changes in Fund Balance

For the Year Ended June 30, 2021

	Stem Cell Fund	Adjustments (Note 3)	Statement of Activities
Revenues:			
General obligation bond revenue	\$ 284,695,000	\$ -	\$ 284,695,000
Commercial paper revenue	10,000,000	-	10,000,000
Licensing and royalty revenue	3,525	-	3,525
Interest on loans	-	678,657	678,657
Investment earnings	3,198,145	-	3,198,145
Total revenues	297,896,670	678,657	298,575,327
Expenditures/expenses:			
Current:			
State operations	12,920,216	241,100	13,161,316
Research grants	95,344,000	-	95,344,000
Total expenditures/expenses	108,264,216	241,100	108,505,316
Excess of revenues over expenditures	189,632,454	(189,632,454)	-
Change in net position	-	190,070,011	190,070,011
Fund balance/net position, beginning of year	70,816,909	36,697,353	107,514,262
Fund balance/net position, end of year	\$ 260,449,363	\$ 37,134,910	\$ 297,584,273

See accompanying notes to the financial statements.

**CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE**  
**(A Component Unit of the State of California)**  
Stem Cell Fund Statement of Expenditures - Budget and Actual  
For the Year Ended June 30, 2021

	Original/ Final Budget	Stem Cell Fund Actual	Variance with Final Budget
Expenditures:			
Current:			
State operations*	\$ 15,337,225	\$ 12,920,216	\$ 2,417,009
Research grants	250,000,000	95,344,000	154,656,000
Total expenditures	\$ 265,337,225	\$ 108,264,216	\$ 157,073,009

\* This figure represents actual Stem Cell Fund administrative overhead expenditures, excluding legal costs, which are included in research grants.

Refer to Health and Safety Code Sections 125290.70(a)(1)(C), 125290.70(a)(2), and 125292.10(u).

See accompanying notes to the financial statements.

## **CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE**

(A Component Unit of the State of California)

Notes to the Basic Financial Statements

For the Year Ended June 30, 2021

### **NOTE 1 – THE FINANCIAL REPORTING ENTITY**

The California Institute for Regenerative Medicine (CIRM) is an agency of the State of California (State) that was established with the passage of Proposition 71, the California Stem Cell Research and Cures Act (the Act). The statewide ballot measure, which provided \$3 billion in funding for stem cell research at universities, research institutions, and companies in California was approved by California voters on November 2, 2004, and called for the establishment of a new state agency to make grants and provide loans for stem cell research, research facilities and other vital research opportunities. The Act authorized the State to issue general obligation bonds and commercial paper to fund CIRM. In July 2012, the State began to issue commercial paper in addition to bonds. CIRM began to receive revenues from the sale of commercial paper and bonds issued by the State to fund CIRM research awards and operations. Proposition 71 authorized the State to issue interim debt such as commercial paper. During the year ended June 30, 2021, CIRM received a total of \$114,060,000 in Proposition 71 funding, which consisted of bond proceeds and commercial paper revenue. On November 3, 2020 voters approved the statewide ballot measure Proposition 14. The passage of Proposition 14, further extended CIRM's mission by establishing the California Stem Cell Research and Cures Act of 2020, providing an additional \$5.5 billion in funding. During the year ended June 30, 2021, CIRM received a total of \$180,635,000 in Proposition 14 funding, which consisted of proceeds from general obligation bonds.

CIRM was established to support stem cell research for the development of regenerative medical treatments and cures and meets the criteria set forth in accounting principles generally accepted in the United States of America (GAAP) as a blended component unit of the State. Although the governing board for CIRM is separate from the State, CIRM is fiscally dependent on the State to provide funding for its operations and the financial burden from general obligation bonds and commercial paper issued is that of the State.

### **NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

#### *A. BASIS OF ACCOUNTING/FUND FINANCIAL STATEMENTS*

Basis of accounting refers to when revenues and expenditures or expenses are recognized in the accounts and reported in the financial statements.

The government-wide financial statements (i.e. the statement of net position and the statement of activities) report information on all of the activities of CIRM. The government-wide financial statements are reported using the economic resources measurement focus and the accrual basis of accounting. Revenues are recorded when earned and expenses are recorded when a liability is incurred, regardless of the timing of related cash flows.

Separate financial statements are provided for CIRM's operating fund, the Stem Cell Fund, a governmental fund. The Stem Cell Fund's financial statements are reported using the current financial resources measurement focus and the modified accrual basis of accounting. Revenues are recognized as soon as they are both measurable and available. Revenues are considered to be available when they are collected within the current period or soon enough thereafter to pay liabilities of the current period. For this purpose, revenues are considered to be available if they are collected within 12 months of the end of the current fiscal period. Expenditures generally are recorded when a liability is incurred, as under accrual accounting.

**CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE**

(A Component Unit of the State of California)

Notes to the Basic Financial Statements (Continued)

For the Year Ended June 30, 2021

**NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)**

**B. ACCOUNTING PRINCIPLES**

The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America and the accounts are maintained by CIRM in accordance with the principles of fund accounting under standards issued by the Governmental Accounting Standards Board (GASB). Fund accounting is the procedure by which resources for various purposes are classified for accounting and reporting purposes into funds established in accordance with their nature and purpose. The operations of the fund are accounted for with a separate set of self-balancing accounts that comprise its assets, deferred outflow of resources, liabilities, deferred inflows of resources, fund equity, revenues, and expenditures.

**C. CASH AND INVESTMENTS**

Cash and investments are reported at amortized cost, which approximates fair value. CIRM maintains its resources in the Surplus Money Investment Fund (SMIF) and operating accounts, which are part of the State Treasurer's pooled investment program. The resources of the SMIF are invested through the Treasurer's Pooled Money Investment Account (PMIA). Investments of the PMIA are restricted by State statutes and regulatory oversight is provided by the Pooled Money Investment Board. Investment income is distributed to the Stem Cell Fund quarterly based on the Fund's relative participation during the quarter. As of June 30, 2021, the weighted average to maturity of the PMIA investments was approximately 291 days. Neither the SMIF nor PMIA are rated by credit rating agencies. Additional information regarding investment risks, including interest rate risk, credit risk and foreign-currency risk of the PMIA can be found in the State's financial statements.

At June 30, 2021, \$260,778,523 was invested in SMIF and \$609,991 was held in the operating accounts of the State Treasury.

**D. LOANS RECEIVABLE**

During the year ended June 30, 2010, CIRM awarded a \$19,999,933 research loan, to be disbursed over a four-year period. During the year ended June 30, 2013, the loan award was amended and increased by \$3,000,000, for a revised loan award of \$22,999,933. CIRM disbursed \$4,993,627 on this loan during the year ended June 30, 2010, \$7,568,869 during the year ended June 30, 2011, \$6,999,704 during the year ended June 30, 2012, \$3,367,733 during the year ended June 30, 2013, \$10,000 during the year ended June 30, 2014, and \$60,000 during the year ended June 30, 2015, for a total loan disbursement of \$22,999,933. On July 1, 2020 the loan was amended to extend the term through February 11, 2026, and the interest rate was lowered to 3% annually on the total outstanding balance, calculated as simple interest. The applicable interest rate prior to the fiscal year on the loan was 8.25%, calculated as simple interest, from the date of each loan disbursement. Repayment of the loan principal and accrued interest is due February 11, 2026, the last day of the 16-year loan period.

**CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE**

(A Component Unit of the State of California)

Notes to the Basic Financial Statements (Continued)

For the Year Ended June 30, 2021

**NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)**

*D. LOANS RECEIVABLE (CONTINUED)*

For the existing loan, various contingencies could affect the amount and schedule for repayment. A total of \$17,702,216 of interest receivable associated with loans has been recorded as of June 30, 2021. The loan and interest receivable balance has been offset by deferred inflows of resources in the Stem Cell Fund as it does not represent available financial resources.

*E. CAPITAL ASSETS AND DEPRECIATION*

In accordance with the State's capitalization policy, capital assets are defined as assets with a useful life of at least one year and a unit acquisition cost of at least \$5,000. Capital assets are reported at historical cost. Equipment is depreciated using the straight-line method over an estimated useful life of 5 years. For the year ended June 30, 2021, there were no acquisitions. At June 30, 2021 all of CIRM's capital assets, which consist entirely of equipment, were fully depreciated and are not reported on the Statement of Net Position.

*F. COMPENSATED LEAVE*

The statement of net position includes unused compensated leave of \$1,248,099 which represents vested unpaid vacation and annual leave. Unused sick leave balances are not accrued as they do not vest to employees. Unused compensated leave is not considered a fund liability as it will not be paid with current financial resources.

*G. POSTEMPLOYMENT BENEFITS*

Eligible employees of CIRM participate in the State's miscellaneous agent multiple-employer defined benefit pension plan which provides retirement and disability benefits, annual cost-of-living adjustments, and death benefits to plan members and beneficiaries. The pension plan is administered by the California Public Employees' Retirement System (CalPERS). In addition, the State also provides eligible retirees post-retirement health care benefits, such as medical, dental, vision and life insurance through its other-postemployment benefits (OPEB) plan. As a governmental fund and bond-funded agency of the State, the State Controller's Office does not allocate CIRM a proportionate share of the State's net pension and OPEB liabilities, and related deferred outflows of resources and deferred inflows of resources for reporting in its annual stand-alone financial report. Further information regarding these plans is available in the State's Annual Comprehensive Financial Report. The report can be found online at [www.sco.ca.gov](http://www.sco.ca.gov).

*H. CLASSIFICATION OF NET POSITION AND FUND BALANCE*

The difference between assets and liabilities and deferred inflows of resources is reported as "fund balance" in the Stem Cell Fund balance sheet and as "net position" in the government-wide statement of net position. CIRM's entire balance of net position is reported as unrestricted net position.



**CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE**

(A Component Unit of the State of California)

Notes to the Basic Financial Statements (Continued)

For the Year Ended June 30, 2021

**NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)**

*H. CLASSIFICATION OF NET POSITION AND FUND BALANCE (CONTINUED)*

To be in conformance with generally accepted accounting principles, CIRM reports fund balance consistent with the GASB Statement No. 54, *Fund Balance Reporting and Governmental Type Definitions*. GASB Statement No. 54 establishes criteria for segregating fund balances into specifically defined classifications and clarifies definitions for governmental funds. GASB Statement No. 54 requires that the fund balances be classified into categories based upon the type of restrictions imposed on the use of the funds. CIRM evaluated its fund balance at June 30, 2021, and classified the balance into the following category:

**Committed:**

Two criteria determine the Committed fund balance:

- Use of funds is constrained by limits imposed by the government's highest level of decision making (for CIRM, this is the Independent Citizens Oversight Committee (ICOC)).
- Removal or modification of use of funds can be accomplished only by formal action of the ICOC which established the constraints.

Both commitments and modification or removal must occur prior to the end of the reporting period; that is, the fiscal year being reported upon. For CIRM, resources in this category would include funding that has been set aside for previously executed legally enforceable contracts but that has not yet been spent, including multi-year contracts, if such contracts have been approved by the ICOC and if funds are redirected, such redirection would require ICOC approval.

*I. RISK MANAGEMENT*

CIRM participates in the State's self-insurance programs. The State is primarily self-insured against loss or liability. The State generally does not maintain reserves; losses are covered by appropriations in the year in which the payment occurs or it becomes fixed and determinable. Information regarding the State's risk management programs is included in the State's Annual Comprehensive Financial Report.

*J. BUDGETARY CONTROL*

The State prepares an annual budget, which is prepared primarily on the modified accrual basis of accounting for governmental funds. Estimated revenues are included in the recommended budget, but revenues are not included in the annual budget bill adopted by the State Legislature. Under State law, the State cannot adopt a spending plan that exceeds estimated revenues. Under the State Constitution, money may be withdrawn from the Treasury only through a legal appropriation. The legal level of budgetary control is at the fund level. CIRM is not a part of the State's annual budget, but instead is continuously appropriated. Budgetary savings in the amount of \$2,417,007 in state operations represents savings in salaries and operating expenditures. Budgetary savings in the amount of \$154,656,000 represents savings in grant research payments and direct legal salaries and operating expenses.

**CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE**

(A Component Unit of the State of California)

Notes to the Basic Financial Statements (Continued)

For the Year Ended June 30, 2021

**NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)**

**K. USE OF ESTIMATES**

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Actual results could differ from those estimates.

**NOTE 3 – RECONCILIATION OF GOVERNMENTAL FUND FINANCIAL STATEMENTS AND GOVERNMENT-WIDE FINANCIAL STATEMENTS**

The fund balance of the Stem Cell Fund differs from net position of governmental activities primarily because of the long-term economic resources focus of the statement of net position versus the current financial resources focus of the governmental fund balance sheet. At June 30, 2021, the differences included the following:

<b>Fund balance</b>	\$ 260,449,363
Capital assets used in the governmental activities are not financial resources, and therefore are not reported in the Fund.	
Capital assets	333,022
Less: accumulated depreciation	<u>(333,022)</u>
	-
Certain long-term assets are not available to pay for current period expenditures and, therefore, are deferred inflows of resources in the Fund — unavailable loans and interest receivable	
	40,702,149
Long-term liabilities are not due and payable in the current period, and therefore are not reported in the Fund.	
Accrued unused compensated leave	(1,248,100)
Payable to State General Fund – SB84 Pension Advance	<u>(2,319,139)</u>
Total long-term liabilities	(3,567,239)
<b>Net position</b>	<u>\$ 297,584,273</u>

**CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE**

(A Component Unit of the State of California)

Notes to the Basic Financial Statements (Continued)

For the Year Ended June 30, 2021

**NOTE 3 – RECONCILIATION OF GOVERNMENTAL FUND FINANCIAL STATEMENTS  
AND GOVERNMENT-WIDE FINANCIAL STATEMENTS (CONTINUED)**

The net change in fund balance for the governmental fund differs from the change in net position for governmental activities primarily because of the long-term economic resources focus of the statement of activities versus the current financial resources focus of the governmental fund. The differences are described below:

**Net change in fund balance** \$ 189,632,454

The Fund does not report capital assets. In the statement of activities however, the cost of capital assets is allocated over their estimated useful lives as depreciation expense.

Depreciation expense (8,136)

Revenue in the statement of activities was recognized for amounts that are deferred in the governmental fund, as amounts do not represent current financial resources. 678,657

Certain expenses reported in the statement of activities do not require the use of current financial resources, and therefore are not reported as expenditures in the governmental fund:

Change in unused compensated leave (232,964)

**Change in net position** \$190,070,011

**NOTE 4 – CAPITAL ASSETS**

Information on changes in capital assets is presented below:

	Balance July 1, 2020	Additions	Reductions	Balance June 30, 2021
Capital Assets				
Equipment:	\$ 333,022	\$ -	\$ -	\$ 333,022
Accumulated Depreciation:	(324,886)	(8,136)	-	(333,022)
Total Capital Assets, Net	<u>\$ 8,136</u>	<u>\$ (8,136)</u>	<u>\$ -</u>	<u>\$ -</u>

**CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE**  
(A Component Unit of the State of California)  
Notes to the Basic Financial Statements (Continued)  
For the Year Ended June 30, 2021

**NOTE 5 – LONG-TERM LIABILITIES**

As of June 30, 2021, unused compensated leave was \$1,248,100 which represents vested unpaid vacation and annual leave.

Changes in Unused Compensated leave are summarized below:

Balance July 1, 2020	Additions	Reductions	Balance June 30, 2021	Due Within One Year	Due in more than One Year
\$ 1,015,136	\$ 590,937	\$ (357,973)	\$ 1,248,100	\$ 69,000	\$ 1,179,100

**NOTE 6 – OFFICE LEASE**

During the fiscal year 2015/16, CIRM entered into an operating lease for office space, the lease expired on March 31, 2021 and CIRM entered into a one year extension through March 31, 2022. Total costs for the lease were \$1,111,172 for the year ended June 30, 2021. Future minimum lease payments required by this lease as of June 30, 2021, are \$813,645. CIRM is currently working on securing a lease for a new property.

**NOTE 7 – RELATED PARTY TRANSACTIONS**

As a component unit of the State of California, other State agencies provided CIRM with various services during the year ended June 30, 2021. The State Controller's Office provided expedited claim schedule processing, California leave accounting system (CLAS) services and EFT services, and CalHR provided training services. The Department of General Services provided accounting services, the Department of Justice provided legal support, the Department of Technology provided accounting system support, and the Public Utilities Commission provides payroll services. Amounts paid for these services for the year ended June 30, 2021, are summarized below:

State Controller's Office	\$ 10,641
CalHR	1,394
Department of General Services	400,345
Department of Justice	2,805
Department of Technology	2,906
Public Utilities Commission	<u>66,000</u>
Total	<u>\$ 484,091</u>

## **Supplementary Information**

**CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE**  
**(A Component Unit of the State of California)**  
Schedule of Revenues, Expenditures and Changes in Available Resources  
For The Year Ended June 30, 2021

	Dolby Grant
Revenues:	
Investment earnings	\$ 1,642
Expenditures:	
Current	
Operating	-
Excess of revenues over expenditures	1,642
Available resources, beginning of year	331,715
Available resources, end of year	\$ 333,357

**CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE**  
**(A Component Unit of the State of California)**  
Stem Cell Fund Combining Balance Sheet  
June 30, 2021

	Stem Cell Fund of 2004	Stem Cell Fund of 2020	Stem Cell Licensing Revenue and Royalties Fund	Total Stem Cell Fund
<b>Assets</b>				
Cash and investments	\$ 82,249,989	\$ 179,135,000	\$ 3,525	\$ 261,388,514
Accounts receivable	42,288	-	-	42,288
Due from other State funds	151,170	115,950	-	267,120
Loans receivable	22,999,933	-	-	22,999,933
Interest receivable	17,702,216	-	-	17,702,216
	<u>123,145,596</u>	<u>179,250,950</u>	<u>3,525</u>	<u>302,400,071</u>
<b>Liabilities</b>				
Accounts payable	923,987	-	-	923,987
Due to other State funds	235,412	89,160	-	324,572
Total liabilities	<u>1,159,399</u>	<u>89,160</u>	<u>-</u>	<u>1,248,559</u>
<b>Deferred inflows of resources</b>				
Unavailable loans and interest receivable	40,702,149	-	-	40,702,149
	<u>41,861,548</u>	<u>89,160</u>	<u>-</u>	<u>41,950,708</u>
<b>Fund balance/net position:</b>				
Fund balance				
Committed	81,284,048	179,161,790	3,525	260,449,363
Total liabilities and deferred inflows and fund balance	<u>\$ 123,145,596</u>	<u>\$ 179,250,950</u>	<u>\$ 3,525</u>	<u>\$ 302,400,071</u>

**CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE**

**(A Component Unit of the State of California)**

Stem Cell Fund Combining Statement of Revenues, Expenditures and Changes in Fund Balance

For the Year Ended June 30, 2021

	Stem Cell Fund of 2004	Stem Cell Fund of 2020	Stem Cell Licensing Revenue and Royalties Fund	Total Stem Cell Fund
Revenues:				
General obligation bond revenue	\$ 104,060,000	\$ 180,635,000	\$ -	\$ 284,695,000
Commercial paper revenue	10,000,000	-	-	10,000,000
Licensing and royalty revenue	-	-	3,525	3,525
Investment earnings	3,082,195	115,950	-	3,198,145
Total revenues	<u>117,142,195</u>	<u>180,750,950</u>	<u>3,525</u>	<u>297,896,670</u>
Expenditures:				
Current:				
State operations	12,831,056	89,160	-	12,920,216
Research grants	93,844,000	1,500,000	-	95,344,000
Total expenditures	<u>106,675,056</u>	<u>1,589,160</u>	<u>-</u>	<u>108,264,216</u>
Excess of revenues over expenditures	10,467,139	179,161,790	3,525	189,632,454
Fund balance, beginning of year	<u>70,816,909</u>	<u>-</u>	<u>-</u>	<u>70,816,909</u>
Fund balance, end of year	<u>\$ 81,284,048</u>	<u>\$ 179,161,790</u>	<u>\$ 3,525</u>	<u>\$ 260,449,363</u>





**Independent Auditor's Report on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with *Government Auditing Standards***

To the Members of the  
Independent Citizens Oversight Committee of the  
California Institute for Regenerative Medicine  
Oakland, California

We have audited, in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States, the financial statements of the governmental activities and the major fund of the California Institute for Regenerative Medicine (CIRM), a component unit of the State of California, as of and for the year ended June 30, 2021, and the related notes to the financial statements, which collectively comprise CIRM's basic financial statements, and have issued our report thereon dated October 29, 2021.

***Internal Control Over Financial Reporting***

In planning and performing our audit of the financial statements, we considered CIRM's internal control over financial reporting (internal control) as a basis for designing audit procedures that are appropriate in the circumstances for the purpose of expressing our opinions on the financial statements, but not for the purpose of expressing an opinion on the effectiveness of CIRM's internal control. Accordingly, we do not express an opinion on the effectiveness of the CIRM's internal control.

*A deficiency in internal control* exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. *A material weakness* is a deficiency, or a combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of the entity's financial statements will not be prevented, or detected and corrected on a timely basis. *A significant deficiency* is a deficiency, or combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.

## **Compliance and Other Matters**

As part of obtaining reasonable assurance about whether CIRM's financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements, noncompliance with which could have a direct and material effect on the financial statements. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.

## **Purpose of this Report**

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the entity's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the entity's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

*Macias Gini & O'Connell LLP*

Sacramento, California  
October 29, 2021